https://scholars.lib.ntu.edu.tw/handle/123456789/639594
標題: | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial | 作者: | Llovet, Josep M Kudo, Masatoshi Merle, Philippe Meyer, Tim Qin, Shukui Ikeda, Masafumi Xu, Ruocai Edeline, Julien Ryoo, Baek-Yeol Ren, Zhenggang Masi, Gianluca Kwiatkowski, Mariusz Lim, Ho Yeong Kim, Jee Hyun Breder, Valeriy Kumada, Hiromitsu ANN-LII CHENG Galle, Peter R Kaneko, Shuichi Wang, Anran Mody, Kalgi Dutcus, Corina Dubrovsky, Leonid Siegel, Abby B Finn, Richard S |
公開日期: | 十二月-2023 | 卷: | 24 | 期: | 12 | 來源出版物: | The Lancet. Oncology | 摘要: | Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639594 | ISSN: | 14702045 | DOI: | 10.1016/S1470-2045(23)00469-2 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。